HER2 testing results, practices, and preferences among pathologists and oncologists in the US community setting: a mixed-methods study.

ABSTRACT:

Purpose

To quantify the proportion of HER2-negative metastatic breast cancers with low or ultralow levels of HER2 expression and identify facilitators and barriers to HER2 testing and reporting in US community settings.

Methods

Analysis of electronic medical record data from a retrospective cohort of patients diagnosed with HER2-negative breast cancer from 2018 to 2023 within the Guardian Research Network, classifying HER2 status by immunohistochemistry (IHC) score. Analysis of responses to surveys of community-based pathologists and oncologists, supplemented by qualitative analysis of one-to-one interview transcripts.

Results

The retrospective study identified 13,824 patients diagnosed with HER2-negative breast cancer from seven healthcare organizations, with 13,100

SUBMITTER: Collin SM 

PROVIDER: S-EPMC12638377 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature